How to improve diagnosis and management of sickle cell disease worldwide
Webinar internazionale FAD sincrono su diagnosi e gestione della malattia drepanocitica (SCD): screening neonatale, terapie innovative (gene editing, hydroxyurea), modelli di cura integrati e accessibilità. 6 crediti ECM.
Questo evento si è concluso il 26 giugno 2026.
Fonte dati per questo evento: Agenas. Evento organizzato da provider terzo. Smart ECM riporta dati pubblici dell'evento a scopo informativo e non è responsabile né del corso né dei contenuti, né ha accordi commerciali o di collaborazione con il provider.
Razionale scientifico
Sickle cell disease (SCD) is one of the most prevalent rare hematological disorders worldwide, affecting millions of individuals across Africa, Europe, the Americas and the Middle East. Although the disease was historically concentrated in specific geographical regions, migration patterns and demographic changes have significantly modified its epidemiology, making SCD an increasingly relevant healthcare challenge in many European countries, including Italy. Despite major scientific and therapeutic advances, important gaps remain in early diagnosis, appropriate clinical management, laboratory monitoring, and access to innovative treatments. Early identification of patients is essential for preventing severe complications and improving long-term outcomes. In this context, laboratory medicine plays a critical role through neonatal screening programs, advanced diagnostic tools, and molecular characterization of hemoglobin variants. In parallel, the therapeutic landscape of SCD is rapidly evolving. Disease-modifying strategies, including optimized hydroxyurea use and new targeted pharmacological agents, are increasingly available. In addition, gene therapy and gene-editing technologies are opening new perspectives for potentially curative approaches. These innovations raise important clinical, regulatory, organizational, and economic questions that require continuous education and multidisciplinary discussion. Healthcare professionals involved in SCD management must therefore be continuously updated on diagnostic advances, laboratory approaches, and emerging therapeutic strategies. Collaboration between clinicians, biologists, and laboratory technicians is essential to ensure appropriate diagnostic pathways, accurate interpretation of laboratory results, and effective patient monitoring. The GARDEN Network CME Webinar 'How to Improve Diagnosis and Management of Sickle Cell Disease Worldwide' aims to provide an updated multidisciplinary overview of the disease, focusing on global diagnostic challenges, innovative models of comprehensive care, emerging therapeutic strategies, and issues related to treatment accessibility and sustainability. The event is specifically designed for medical doctors, biologists, and laboratory technicians working in hematology and rare diseases, with the objective of improving diagnostic accuracy, strengthening collaboration between clinical and laboratory professionals, and facilitating the translation of scientific advances into routine clinical practice.
Programma
26 June 2026 – GARDEN Webinar· FAD Sincrona – piattaforma https://infomed-ecm.it/
- 09:00–09:15Welcome & Opening Remarks. Overview of global SCD burden and objectives of the webinar
- FIRST SESSION: Global Barriers to Early Diagnosis of SCD
- 09:15–09:30Bridging the Access Gap for Comprehensive Sickle Cell Disease Management Across Sub-Saharan Africa: Learnings for Other Global Health Interventions?L. Tshilolo
- 09:30–09:45Neonatal screening for SCD in Italy: Low Cost and Reproducible Program in an Area of Immigration of High Risk PopulationD. Venturelli
- 09:45–10:00Sickle cell disease in Germany. Results from a national registry: which are the unmet needs?S. Lobitz
- SECOND SESSION: Innovative Models of Comprehensive Care
- 10:00–10:15Comprehensive care management in pediatrics age of SCDR. Colombatti
- 10:15–10:30Transition from pediatric to adult careC. Minniti
- 10:30–10:45Comprehensive approach for SCD care centersJ. Telfer
- 10:45–11:00After two decades of hydroxyurea: leukemic risk in sickle cell disease assessed by integrated marrow morphology, cytogenetics and genomicsA. Maggio
- 11:00–11:15Break
- THIRD SESSION: New Therapeutic Strategies: From Disease-Modifying Agents to Curative Approaches
- 11:15–11:35Current and innovative treatments approach management of SCD in FranceM. De Montalembert
- 11:35–11:55Sickle Cell Disease management in UK: impact of Gene Editing treatmentD. Rees
- 11:55–12:15New insights on the hematopoiesis disorders in SCDL. De Franceschi
- FOURTH SESSION: Accessibility, HTA and Sustainability of SCD Treatments
- 12:15–13:15Discussion on actionable recommendations for 2027. Speakers: Representatives of Regulatory Agencies, Representatives of low-resource countries, Representatives of the Project Italy-Tunisia ETIC, Patient Association Representative, Nurse Specialist, Psychologist
- 13:15–13:30Closing Remarks & Action Points. Summary of key messages. Proposal for GARDEN SCD Position Paper. Future collaborative initiatives
Responsabili del corso
IN&FO&MED S.R.L.
Provider
ID Provider: N° 275
Città: Milano (MI)
Tipologia: Società, Agenzie Ed Enti Privati
Stato accreditamento: Standard - 1° Rinnovo
Prof. Aurelio Maggio
Responsabile scientifico
Specializzazione: Ematologia
Struttura: Fondazione Franco e Piera Cutino, Palermo; Villa Sofia-Cervello Palermo
Ruolo: Presidente Fondazione Cutino e Medico Ematologo
Relatori e docenti
Prof.ssa Raffaella Colombatti
Relatore
Specializzazione: Pediatria, Oncoematologia Pediatrica
Struttura: Azienda Ospedale-Università di Padova
Ruolo: Professore Associata di Pediatria, Università di Padova; Direttore funzionale Centro di Riferimento Regione Veneto per la Diagnosi, cura e trattamento della Malattia Drepanocitica in Età Pediatrica
Prof. Lucia De Franceschi
Relatore
Specializzazione: Medicina Interna
Struttura: Università degli Studi di Verona
Ruolo: Professor of Internal Medicine, DIMI, Università di Verona
Prof. Mariane De Montalembert
Relatore
Specializzazione: Pediatria, malattie del globulo rosso (emoglobinopatie), trasfusione
Struttura: Hôpital Necker-Enfants malades, Paris (France); Paris Descartes University
Ruolo: Professor, Pediatrics Department and Sickle Cell Clinic, Hospital Necker, AP-HP
Stephan Lobitz
Relatore
Specializzazione: Ematologia pediatrica (SCD, emoglobinopatie)
Struttura: Gemeinschaftsklinikum Mittelrhein gGmbH, Koblenz (Germany)
Ruolo: Head of Pediatric Hematology and Oncology
Cesare Medri
Relatore
Prof. Caterina Minniti
Relatore
Specializzazione: Ematologia pediatrica
Struttura: Albert Einstein College of Medicine, NY (USA)
Ruolo: Professor Emeritus of Medicine and Pediatrics
David Charles Rees
Relatore
Specializzazione: Ematologia pediatrica (SCD, talassemia, porfiria)
Struttura: King's College London; King's College Hospital
Ruolo: Paediatric haematologist
Prof. Paul Telfer
Relatore
Specializzazione: Ematologia clinica (emoglobinopatie)
Struttura: Queen Mary University of London – Blizard Institute; Bart's Health NHS Trust
Ruolo: Professor and clinical lead for haemoglobinopathy services; lead for Haemoglobinopathy Co-ordinating Centres
Donatella Venturelli
Relatore
Specializzazione: Medicina e Chirurgia
Struttura: Università degli Studi di Modena e Reggio Emilia
Ruolo: Dirigente medico I livello con incarico professionale semplice – Sorveglianza e profilassi della Malattia Emolitica Neonatale e della diagnosi perinatale delle emoglobinopatie congenite
Domande frequenti
L'evento è accreditato per: Medico Chirurgo (Pediatria); Biologo (Biologo); Medico Chirurgo (Medicina Interna, Ematologia); Infermiere (Infermiere); Tecnico Sanitario Laboratorio Biomedico (Tecnico Sanitario Laboratorio Biomedico).
Fonte dati per questo evento: Agenas. Evento organizzato da provider terzo. Smart ECM riporta dati pubblici dell'evento a scopo informativo e non è responsabile né del corso né dei contenuti, né ha accordi commerciali o di collaborazione con il provider.